Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02662062
Title Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (PCR-MIB)
Acronym PCR-MIB
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.